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Background:   Prostatitis is a common condition which can affect men of all ages; 
however, it is more frequently experienced in younger men with an initial onset 
around 40 years of age.  The two main presenting clinical features of prostatitis are 
lower urinary tract symptoms and pelvic pain.  Other symptoms might include 
obstructive or irritative voiding symptoms, ejaculatory pain, and haematospermia. A 
diagnosis is usually based on the man's history, physical examination, urinalysis and 
the two- or four-glass test (also known as obtaining urine specimens before, during, 
and after prostatic massage). Further investigations may also be performed when 
considering the differential diagnosis. Prostatitis can result in a significant reduction 
in quality of life (QOL) and pain can be associated with sexual dysfunction in men.  
 
Prostatitis can be classified as four distinct types, namely: types I acute prostatitis, 
type II chronic bacterial prostatitis, type III chronic prostatitis/chronic pelvic pain 
syndrome (CP/CPPS), and type IV being asymptomatic prostatitis. It is unclear 
whether type III can be linked in all cases to prostatic involvement therefore the 
alternate denomination CPPS is used in clinical practice. Furthermore, CP/CPPS is 
further sub-classified as type IIIa (inflammatory), and type IIIb (noninflammatory) 
which is dependent on the presence of inflammatory cells in prostatic secretions. 
CP/CPPS is considered when pelvic pain is present for at least three of the 
preceding six months with no other identifiable causes determined. 
 
There are several hypothesised causes of CP/CPPS which include: 
neuropsychological factors, infection, inflammation/autoimmunity and dyssynergic 
voiding associated with bladder neck hypertrophy.   Given the wide range of potential 
causes of CP/CPPS there are many pharmacological interventions available in 
clinical practice to manage this complex condition.  It is important to critically 
summarise evidence-based recommendations to inform the clinical management of 
men affected by CP/CPPS. 
 
Objective/s: The overall aim was to assess the effects of pharmacological therapies 
for chronic prostatitis/chronic pelvic pain syndrome.  The primary outcomes were 
prostatitis symptoms and adverse events.  Secondary outcomes of interest were 
sexual dysfunction, quality of life, depression and anxiety and urinary symptoms.  
Participants in randomised controlled trials were men of all ages, suffering from 
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) according to the type III 
classification.  
 
Intervention/Methods: Studies compared individual pharmacological interventions 
which included: alpha blockers, 5-alpha reductase inhibitors, antibiotic therapy 
(quinolones, tetracyclines and other agents), anti-inflammatories (nonsteroidal anti-
inflammatory drugs [NSAIDs], corticosteroids), phytotherapy (pollen extract and 
bioflavonoids), botulinum toxin A, allopurinol, traditional medicine (traditional Chinese 
medicine, etc.), other pharmacological agents, or combination therapies head-to-
head with placebo, no treatment or other types of pharmacological interventions. 
Comparator’s included for example, alpha blockers plus quinolones versus placebo, 
or alpha blockers versus placebo.  The researchers sought to determine whether 
individual or multimodal pharmacological interventions were more effective compared 
to the control in outcomes (prostatitis symptoms, adverse events, sexual dysfunction, 
QoL, depression and anxiety) measured up to and including 12 months after 
randomisation as short-term, and later than 12 months as long-term. 
 
Results:  Ninety-nine RCT studies and a total of 9119 participants, who were men 
with CP/CPPS, were included. The included studies conducted assessments of all 
available pharmacological interventions compared to placebo or in head-to-head 
comparisons. Sixteen pharmacological interventions were included and most 
comparisons were based on short-term follow-up (less than 12 months). Twenty-one 
studies were funded by pharmaceutical companies and the rest did not report 
funding sources.   
The reviewers were uncertain about the effects of Alpha blockers on prostatitis 
symptoms when compared to placebo at both short- and long-term follow-up. Alpha 
blockers may be associated with an increased incidence of adverse events, such as 
dizziness and postural hypotension. The findings suggest that Alpha blockers 
probably result in little to no difference in sexual dysfunction, quality of life and 
anxiety and depression. 
 
The findings (based on moderate – low quality of evidence) suggest that antibiotics, 
anti-inflammatories, intraprostatic botulinum A injection, traditional Chinese medicine, 
mepartricin and phosphodiesterase inhibitors may improve prostatitis symptoms in 
the short term with limited adverse events. Moderate-quality evidence identified that 
phytotherapy and 5-alpha reductase inhibitors may improve prostatitis symptoms, but 
these interventions can be associated with a greater incidence of decreased libido, 
fatigue, mood change and gastrointestinal discomfort.  
 
Conclusions:  The authors of this review conclude there exists mainly low- to very 
low-quality evidence that alpha blockers, antibiotics, 5-ARI, anti-inflammatories, 
phytotherapy, intraprostatic BTA injection, and traditional Chinese medicine may 
reduce prostatitis symptoms without increased incidence of adverse events in the 
short term. This excludes alpha blockers which may be associated with an increase 
in mild adverse events. Few trials have been conducted with active comparators and 
therefore little evidence exists of the effects of these drugs on sexual dysfunction, 
quality of life or anxiety and depression. More rigorous research is required as the 
current evidence base offers little guidance for nurses as to effective pharmaceutical 
interventions for CP/CPPS.  
 
Future research should ensure adequate study design, sample size and follow up 
longer than 12 weeks. Overall uncertainty about the true effects of a range of 
available interventions evidence in this review means we can have limited confidence 
in these results for clinical decision-making. Treatment decisions about the 
appropriate pharmacological intervention should be aligned to the symptoms being 
experienced, the safety profile of each agent and the patient's values and 
preferences.  
 
Implications for Practice:  CP/CPPS syndrome is a relatively common condition in 
men over the age of 40 years old.  CP/CPPS is complex condition to treat and is 
debilitating for men which can negatively affect QOL.  Nurses are a key member of 
the multidisciplinary team and can support patients by developing shared self-
management care plans based upon evidence-based recommendations identified in 
this review.  There were varying levels of evidence across a wide range of 
pharmacological interventions to treat CP/CPPS which has informed clinical practice.   
 
Importantly, nurses should be aware that there was low- to very low-quality evidence 
to support the use of alpha blockers with increased risk of hypotension and 
dizziness.  Whereas other interventions including antibiotics, anti-inflammatories, 
intraprostatic botulinum A injection, traditional Chinese medicine, mepartricin and 
phosphodiesterase inhibitors may improve prostatitis symptoms with limited adverse 
events. Noteworthy, moderate-quality evidence identified that phytotherapy and 5-
alpha reductase inhibitors may improve prostatitis symptoms, but these interventions 
can be associated with a greater incidence of decrease libido, fatigue, mood change 
and gastrointestinal discomfort. 
 
Nurses must ensure that patients are informed of the evidence-base 
recommendations for different pharmacological interventions to treat CP/CPPS and 
men must be carefully counselled about the potential adverse events which may 
further impact QOL.  
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